Drug intelligence / Profile preview

JLP-2004

Development stage: Phase 1
Lead developer: Jeil Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JLP-2004 is an incrementally modified drug (IMD) under development by Jeil Pharmaceutical for the treatment of pain, osteoarthritis, rheumatoid arthritis, and back pain. It is a small molecule cyclooxygenase type 2 (COX-2) inhibitor administered orally in tablet form. The drug is currently in Phase 1 clinical trials for rheumatoid arthritis and has also been studied in healthy volunteers to evaluate its safety and pharmacokinetic characteristics. As a COX-2 inhibitor, JLP-2004 works by selectively inhibiting the cyclooxygenase type 2 enzyme, which plays a key role in inflammation and pain pathways[1][3][4].

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on JLP-2004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JLP-2004.

Explore the full profile